Reposted by Anup
T0b: #NephJC
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
July 9, 2025 at 1:10 AM
T0b: #NephJC
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
Reposted by Anup
With rising burden of metabolic diseases we are struggling with management of ascites in CKD. Here we try to answer them & provide an overview of approach to ascites in ESRD. @ebtapper.bsky.social @akashroyy.bsky.social
journals.lww.com/hepcomm/full...
journals.lww.com/hepcomm/full...
Ascites in patients with end-stage renal disease:... : Hepatology Communications
d. However, patients with end-stage renal disease (ESRD) may also present with ascites even in the absence of cirrhosis. The literature on the management of patients with ESRD with ascites with or wit...
journals.lww.com
April 3, 2025 at 5:17 PM
With rising burden of metabolic diseases we are struggling with management of ascites in CKD. Here we try to answer them & provide an overview of approach to ascites in ESRD. @ebtapper.bsky.social @akashroyy.bsky.social
journals.lww.com/hepcomm/full...
journals.lww.com/hepcomm/full...
Reposted by Anup
Rhabdomyolysis induced AKI: Key 🔑 pathobiological processes and management interventions ca. 2023 #Nephpearls
👉🏼 journals.lww.com/cjasn/pages/...
👉🏼 journals.lww.com/cjasn/pages/...
January 18, 2024 at 3:37 AM
Rhabdomyolysis induced AKI: Key 🔑 pathobiological processes and management interventions ca. 2023 #Nephpearls
👉🏼 journals.lww.com/cjasn/pages/...
👉🏼 journals.lww.com/cjasn/pages/...
Reposted by Anup
Finerenone trials
#PSHPLAS 🇵🇭 #Nephpearls #NephSky
👉🏼 FIDELIO pubmed.ncbi.nlm.nih.gov/33264825/
👉🏼 FIGARO pubmed.ncbi.nlm.nih.gov/34449181/
👉🏼 FIDELITY pubmed.ncbi.nlm.nih.gov/35023547/
👉🏼 FINE-HEART pubmed.ncbi.nlm.nih.gov/39218030/
#PSHPLAS 🇵🇭 #Nephpearls #NephSky
👉🏼 FIDELIO pubmed.ncbi.nlm.nih.gov/33264825/
👉🏼 FIGARO pubmed.ncbi.nlm.nih.gov/34449181/
👉🏼 FIDELITY pubmed.ncbi.nlm.nih.gov/35023547/
👉🏼 FINE-HEART pubmed.ncbi.nlm.nih.gov/39218030/
February 28, 2025 at 10:29 AM
Finerenone trials
#PSHPLAS 🇵🇭 #Nephpearls #NephSky
👉🏼 FIDELIO pubmed.ncbi.nlm.nih.gov/33264825/
👉🏼 FIGARO pubmed.ncbi.nlm.nih.gov/34449181/
👉🏼 FIDELITY pubmed.ncbi.nlm.nih.gov/35023547/
👉🏼 FINE-HEART pubmed.ncbi.nlm.nih.gov/39218030/
#PSHPLAS 🇵🇭 #Nephpearls #NephSky
👉🏼 FIDELIO pubmed.ncbi.nlm.nih.gov/33264825/
👉🏼 FIGARO pubmed.ncbi.nlm.nih.gov/34449181/
👉🏼 FIDELITY pubmed.ncbi.nlm.nih.gov/35023547/
👉🏼 FINE-HEART pubmed.ncbi.nlm.nih.gov/39218030/
Reposted by Anup
Lorundrostat - an aldosterone synthase inhibitor.
Lorundrostat was associated with greater reductions in 24-hr average BP than placebo in pts with uncontrolled & treatment-resistant hypertension.
K level >6.0 occurred in 5 pts (5%) in the stable-dose group.
www.nejm.org/doi/full/10....
@nejm.org
Lorundrostat was associated with greater reductions in 24-hr average BP than placebo in pts with uncontrolled & treatment-resistant hypertension.
K level >6.0 occurred in 5 pts (5%) in the stable-dose group.
www.nejm.org/doi/full/10....
@nejm.org
April 27, 2025 at 1:08 AM
Lorundrostat - an aldosterone synthase inhibitor.
Lorundrostat was associated with greater reductions in 24-hr average BP than placebo in pts with uncontrolled & treatment-resistant hypertension.
K level >6.0 occurred in 5 pts (5%) in the stable-dose group.
www.nejm.org/doi/full/10....
@nejm.org
Lorundrostat was associated with greater reductions in 24-hr average BP than placebo in pts with uncontrolled & treatment-resistant hypertension.
K level >6.0 occurred in 5 pts (5%) in the stable-dose group.
www.nejm.org/doi/full/10....
@nejm.org
Reposted by Anup
April 11, 2025 at 5:22 PM
Reposted by Anup
Hey #NephSky & #MedSky
9pm EST 4/15/25, only on #Bluesky
Discussion on the use of metformin in advanced CKD.
Worried about lactic acidosis 💪?!
What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️?
Are there benefits to continuing 💊
www.nephjc.com/news/metformin-tte
9pm EST 4/15/25, only on #Bluesky
Discussion on the use of metformin in advanced CKD.
Worried about lactic acidosis 💪?!
What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️?
Are there benefits to continuing 💊
www.nephjc.com/news/metformin-tte
Metformin- Should I Stay or Should I Go — NephJC
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
www.nephjc.com
April 15, 2025 at 2:33 AM
Hey #NephSky & #MedSky
9pm EST 4/15/25, only on #Bluesky
Discussion on the use of metformin in advanced CKD.
Worried about lactic acidosis 💪?!
What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️?
Are there benefits to continuing 💊
www.nephjc.com/news/metformin-tte
9pm EST 4/15/25, only on #Bluesky
Discussion on the use of metformin in advanced CKD.
Worried about lactic acidosis 💪?!
What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️?
Are there benefits to continuing 💊
www.nephjc.com/news/metformin-tte
